Investigating SNORD3A in heart disease and heart failure
ROLE OF CIRCULATING SMALL NUCLEOLAR RNA SNORD3A IN ISCHEMIC HEART DISEASE AND HEART FAILURE
This study is testing how a specific gene might be linked to heart disease and heart failure by looking at patients with heart issues and healthy volunteers over two years.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Federico II University Academic / other |
| Locations | 1 site (Naples) |
| Trial ID | NCT06678802 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enroll patients with chronic ischemic heart disease or acute coronary syndromes undergoing coronary angiography and potential revascularization. It will also include healthy volunteers as a control group. Participants will undergo clinical evaluations, ECGs, echocardiography, and blood sampling at various time points to analyze peripheral blood mononuclear cells and conduct standard blood tests. The study will last for 24 months and is expected to involve around 450 participants.
Who should consider this trial
Good fit: Ideal candidates include patients with chronic ischemic heart disease or acute coronary syndromes, as well as healthy volunteers without a history of ischemic heart disease.
Not a fit: Patients with concomitant primary cardiomyopathies or significant heart valve disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the role of SNORD3A in ischemic heart disease and heart failure, potentially leading to improved diagnostic or therapeutic strategies.
How similar studies have performed: While this approach is observational and may have been explored in other contexts, the specific focus on SNORD3A in this patient population is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Group 1: History (\> 6 months) of ischemic heart disease (prior myocardial infarction, prior percutaneous coronary intervention, prior surgical revascularization) and clinical or imaging evidence of chronic moderate or severe myocardial ischemia Group 2: Patients with acute coronary syndromes at presentation including ST-elevation myocardial infarction, Non-ST elevation myocardial infarction, and unstable angina. Group 3: Healthy volunteers with no prior history of ischemic heart disease or clinical/imaging evidence of myocardial ischemia. Exclusion Criteria: Patients unwilling to provide informed consent to participate to the study * Concomitant primary cardiomyopathies or hemodynamically significant heart valve disease * Treatment with cancer or antibiotic therapies affecting ribosomal structure or function.
Where this trial is running
Naples
- Federico II University Hospital — Naples, Italy (Recruiting)
Study contacts
- Study coordinator: Cinzia Perrino, MD PhD
- Email: perrino@unina.it
- Phone: 00390817462223
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.